COMMUNIQUÉS West-GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences
03/04/2024
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]
Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use
03/04/2024
Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use 53.8% of Medical Cannabis Patients in Study Reported a Decrease on Prescription Opioid Use [...]
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium
03/04/2024
BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer [...]
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
03/04/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a brief market [...]
Aveanna Healthcare Holdings Announces Appointment of Chief Legal Officer and Secretary
03/04/2024
ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/04/2024
LOS ANGELES and NIMES, France, April 03, 2024 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes, today announced [...]
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/04/2024
Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211 programs through key data [...]
TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors
03/04/2024
Dr. Alpern brings extensive clinical trialing experience in ophthalmology CHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc. , a privately held biotech company developing potentially disruptive [...]
MannKind Repays Certain Debt Obligations
03/04/2024
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and [...]
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases
03/04/2024
- DIAGONAL platform, combining proprietary computational and experimental techniques to identify rare agonist antibodies that reactivate deficient signaling pathways, has generated a pipeline of novel therapeutics - [...]
RadNet Announces a Proposed Refinancing of its Term Loan and Revolving Credit Facility
03/04/2024
LOS ANGELES, April 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced a proposed [...]
GUERBET : Mise à disposition du Document d’enregistrement universel 2023
03/04/2024
Mise à disposition du Document d’enregistrement universel 2023 Villepinte, le 3 avril 2024 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, a déposé son [...]
Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
03/04/2024
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products [...]
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
03/04/2024
OMX-0407: clinical-stage, spectrum selective SIK kinase inhibitor with dual effect on tumor growth and immune evasion IOMX-0675: best-in-class antibody targeting immunosuppressive receptors LILRB1 & LILRB2 on immune [...]
CancerVax Launches $5 Million Funding Round
03/04/2024
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments Lehi, Utah, April 03, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., developer of a breakthrough [...]
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)
03/04/2024
GLASGOW, Scotland, April 03, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the [...]
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC
03/04/2024
Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert [...]
Pharming Group to participate in April investor conferences
03/04/2024
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month [...]
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
03/04/2024
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus [...]

Pages